Table 1.
Correlation of clinical characteristics with DDX23 expression.
| Clinical characteristics | DDX23 expression | P value | |||
|---|---|---|---|---|---|
| Total (n = 124) | Low expression (n = 82) | High expression (n = 42) | |||
| Age (years) | <56 | 55 (44.4) | 37 (45.1) | 18 (42.9) | 0.810 |
| ≥56 | 69 (55.6) | 45 (54.9) | 24 (57.1) | ||
| FIGO stage (2014) | I and II | 26 (21.0) | 17 (20.7) | 9 (21.4) | 0.928 |
| II and III | 98 (79.0) | 65 (79.3) | 33 (78.6) | ||
| Histology | HGSOC | 103 (83.1) | 68 (82.9) | 35 (83.3) | 0.404 |
| Non-HGSOC | 8 (6.5) | 6 (7.3) | 2 (4.8) | ||
| Unknown | 13 (10.5) | 8 (9.8) | 5 (11.9) | ||
| Grade | II (moderately) | 8 (6.5) | 6 (7.3) | 2 (4.8) | 0.859 |
| III (poorly) | 110 (88.7) | 72 (87.8) | 38 (90.5) | ||
| Unknown | 6 (4.8) | 4 (4.9) | 2 (4.8) | ||
| Ascites | Yes | 23 (18.5) | 14 (17.1) | 9 (21.4) | 0.706 |
| No | 7 (5.6) | 4 (4.9) | 3 (7.1) | ||
| Unknown | 94 (75.8) | 64 (78.0) | 30 (71.4) | ||
| CA-125 (U/mL) | <785 | 58 (46.8) | 36 (43.9) | 22 (52.4) | 0.371 |
| ≥785 | 66 (53.2) | 46 (56.1) | 20 (47.6) | ||
| Tumor diameter (cm) | <8 | 37 (29.8) | 27 (32.9) | 10 (23.8) | 0.294 |
| ≥8 | 87 (70.2) | 55 (67.1) | 32 (76.2) | ||
| Residual disease (cm) | <1 | 51 (41.1) | 38 (46.3) | 13 (31.0) | 0.099 |
| ≥1 | 73 (58.9) | 44 (53.7) | 29 (69.0) | ||
| Adjuvant chemotherapy | Yes | 122 (98.4) | 81 (98.8) | 41 (97.6) | 1.000 |
| No | 2 (1.6) | 1 (1.2) | 1 (2.4) | ||
| Death | Yes | 103 (83.1) | 64 (78.0) | 39 (92.9) | 0.037 |
| No | 21 (16.9) | 18 (22.0) | 3 (7.1) | ||
| Follow-up time (month) | 45.5 (1-159) | 49 (1-159) | 41.5 (1-110) | 0.166 | |
Values are present as n (%) or median (range). DDX23, DEAD-Box Helicase 23; FIGO, International Federation of Gynecology and Obstetrics; HGSOC, high-grade serous ovarian carcinoma; CA-125, Cancer Antigen 125.